Search
Now showing items 1-1 of 1
Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue, PSA146-154
(Hindawi Publishing Corporation, 2010)
Twenty eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate specific antigen, PSA146-154, between July 2002 to September ...